|
WASF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.82565074169361E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.74169999533902E-08 |
| Normal-vs-Stage2 |
3.327800E-02 |
| Normal-vs-Stage3 |
2.33910000257964E-08 |
| Normal-vs-Stage4 |
3.33990002321372E-09 |
| Stage1-vs-Stage2 |
2.323900E-02 |
| Stage1-vs-Stage3 |
1.104840E-01 |
| Stage1-vs-Stage4 |
6.640400E-01 |
| Stage2-vs-Stage3 |
1.896620E-01 |
| Stage2-vs-Stage4 |
6.382500E-03 |
| Stage3-vs-Stage4 |
2.563800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.85296222809939E-12 |
| Normal-vs-AfricanAmerican |
1.538190E-01 |
| Normal-vs-Asian |
8.06600000013979E-07 |
| Caucasian-vs-AfricanAmerican |
5.505000E-01 |
| Caucasian-vs-Asian |
7.765200E-01 |
| AfricanAmerican-vs-Asian |
5.203200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.68360003716117E-09 |
| Normal-vs-Female |
1.04049990845567E-10 |
| Male-vs-Female |
9.376300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.96500000004818E-06 |
| Normal-vs-Age(41-60Yrs) |
4.91639999822269E-08 |
| Normal-vs-Age(61-80Yrs) |
3.824200E-04 |
| Normal-vs-Age(81-100Yrs) |
2.608400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.412600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.599690E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.962400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.237800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.052600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.765800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.402600E-01 |
| Classical-VS-Follicular |
4.671800E-02 |
| Classical-VS-Other |
4.709200E-01 |
| Classical-VS-Normal |
1.11022302462516E-16 |
| Tall-VS-Follicular |
2.366400E-02 |
| Tall-VS-Other |
5.194200E-01 |
| Tall-VS-Normal |
1.51769999900964E-08 |
| Follicular-VS-Other |
2.993200E-01 |
| Follicular-VS-Normal |
2.924200E-01 |
| Other-VS-Normal |
2.249000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.9771999999958E-05 |
| Normal-vs-N1 |
4.86130025123543E-10 |
| N0-vs-N1 |
6.387700E-02 |
|
|
